It's 1963. Professor Raphael Mechoulam becomes the first scientist to isolate and synthesize the active components of the cannabis plant. Which ones? THC, CBD , and several other cannabinoids. Later, in 1988, he makes headlines again. His laboratory discovers the endocannabinoid system (ECS). All these contributions to the advancement of cannabis science make Raphael Mechoulam the "godfather" of research in this field. Indeed, his discoveries have shaped and transformed the world of medical research related to cannabis.
The summary
- Another line added to the genius's CV!
- An even greater elite of geniuses
- Reassuring scientific data!
Another line added to the genius's CV!
In fact, the professor is still at work. Indeed, this genius is leading the EPM medical team, which plans to list on the Tel Aviv Stock Exchange towards the end of 2021.
The medical team's research aims to uncover the potential of cannabis acids as an alternative medicine for several diseases, including Crohn's disease, colitis, and epilepsy. To this end, the team has replicated the structures of cannabis acids, enabling their large-scale production without the need for live plants. EPM CEO Reshef Swisacommented on this in an interview with the Jerusalem Post.
"So far we have developed 14 different molecules, eight of which are completely new discoveries, which means we have a very exclusive patent on them, as they are a new discovery for the scientific world.".
Swisa added…
"Each of these molecules has the potential to be developed into multiple drugs, while many companies can do incredible things with even just a single molecule."
An even greater elite of geniuses
Indeed, these researchers are not the only ones exploring the potential of plants in this sector. Swisa cited the example of the epilepsy drug Epidiolex, which British pharmaceutical businessman Julian Gangolli helped launch. The drug became the first cannabis derivative approved by the FDA in 2018. Gangolli commented on this.
"We had children who had 40 or 50 epileptic seizures per week, which this product was able to reduce to very few and even without seizures.".
There are others of this type. In fact, many medications come from plants. This is the case with the drug aspirin. Aspirin is a synthetic version of salicylic acid, which is derived from willow bark.
Reassuring scientific data!
The data already available is increasingly reassuring patients. Indeed, Swisa has stated that their tests for colitis have shown that synthesized cannabis acids outperform CBD treatments. Furthermore, these acids work in the same way as standard treatments and steroids on the market. This discovery is quite significant. Why? Because steroids have a considerable number of side effects, including a weakening of the immune system. Swisa elaborates on this point.
"The more we investigated, the more we saw that we have a potential new alternative to probably two of the most horrific diseases you can find today.".
He continues…
"Crohn's disease and colitis are life-destroying. Right now, they are forced to choose between the bad and the terrible."
In addition, EPM has discovered that synthetic cannabis acids have the potential to treat obesity, lung inflammation, nausea, depression, anxiety, and skin disorders such as psoriasis and atopic dermatitis.
References
- http://cannadaily.news/the-godfather-of-cannabis-medical-research-transforms-again-the-industry/
Co-founder of CBD.fr
Julien Cordobes is the editor of CBD.fr. Born in 1978 in the Paris region, he first trained in e-commerce before turning to natural health approaches, a dual perspective that now structures his way of writing about cannabidiol: reading the scientific literature as it is, without hardening the conclusions, and presenting it in a language that everyone understands.
He discovered CBD at a time when the French market was developing faster than the information available to it. He acquired CBD.fr in 2022 and then took on editorial responsibility for the blog. Since then, he has published numerous articles covering the daily use of CBD, the interpretation of laboratory analyses, the evolution of the legal framework, and precautions for use.
